Kalaris Therapeutics Inc. – Indentures

NASDAQ: KLRS
Share price (6/2/26): $4.65
Market cap (6/2/26): $111 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Indentures Filter

EX-4.6

from S-3 7 pages Form of Subordinated Note

12/34/56

EX-4.5

from S-3 7 pages Form of Senior Note

12/34/56

EX-4.4

from S-3 47 pages Kalaris Therapeutics, Inc. and Trustee Indenture Dated as of Subordinated Debt Securities

12/34/56

EX-4.3

from S-3 42 pages Kalaris Therapeutics, Inc. and Trustee Indenture Dated as of Senior Debt Securities

12/34/56

EX-4.1

from 10-K 4 pages Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934

12/34/56

EX-4.1

from 8-K 16 pages Form of Pre-Funded Warrant to Purchase Common Stock

12/34/56

EX-4.5

from S-4/A 6 pages Convertible Promissory Note

12/34/56

EX-4.4

from S-4/A 40 pages Kalaris Therapeutics, Inc. Note Purchase Agreement

12/34/56

EX-4.3

from S-4/A 7 pages Convertible Promissory Note

12/34/56

EX-4.4

from S-3ASR 37 pages Allovir, Inc. Issuer and [Trustee], Trustee Indenture Dated as of [ ] Subordinated Debt Securities

12/34/56

EX-4.3

from S-3ASR 35 pages Allovir, Inc. Issuer and [Trustee], Trustee Indenture Dated as of [ ] Senior Debt Securities

12/34/56

EX-4.2

from 10-K 5 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Description of Capital Stock

12/34/56

EX-4.1

from S-1/A 2 pages Indenture or similar

12/34/56

EX-4.2

from S-1 100 pages Viracyte, Inc. Amended and Restated Investors’ Rights Agreement

12/34/56

EX-4.2

from DRS 100 pages Viracyte, Inc. Amended and Restated Investors’ Rights Agreement

12/34/56

Kalaris Therapeutics Inc. – Indentures Watch

Search in Documents

Key Exhibits

External Links

Indentures Filter

Kalaris Therapeutics Inc. – Indentures